Table 2:

Results for the interventional autoregressive integrated moving average model summarizing the association of the COVID-19 pandemic and monthly age-standardized incidence rates for new pediatric cancer diagnoses per million population

ParameterARIMA (p d q)(P D Q)12*Level shift interventionTrend change intervention
Estimate of β (95% CI)p valueEstimate of β (95% CI)p value
Cancer type
 All cancers combined(1 0 0)(0 0 0)**4.98 (−15.1 to 25.04)0.6−2.09 (−5.63 to 1.44)0.25
 Leukemia and lymphoma(1 0 0)(0 0 0)10.27 (−0.72 to 23.25)0.1−1.00 (−3.27 to 1.27)0.4
 CNS tumour(0 0 0)(0 1 1)**−5.11 (−11.7 to 1.45)0.1NA
 Extracranial solid tumour(0 0 0)(0 1 1)**−1.33 (−11.4 to 8.73)0.8NA
Geographic region
 Atlantic§(1 0 1)(0 0 0)11.98 (0.38.3 to 62.22)0.6NA
 Quebec(1 0 1)(0 0 0)−16.0 (−51.1 to 19.12)0.4NA
 Ontario(2 0 0)(0 0 0)−7.09 (−32.6 to 18.42)0.6NA0.7
 Prairies(0 1 1)(0 1 1)−38.7 (−126.0 to 48.41)0.4NA
 British Columbia(0 0 0)(0 0 0)25.22 (−3.01 to 53.45)0.09NA
  • Note: ARIMA = autoregressive integrated moving average, ASIR = age-standardized incidence rate, CI = confidence interval, CNS = central nervous system, NA = not applicable.

  • * For methodological considerations regarding ARIMA models, see Appendix 1, Supplement 2, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.210659/tab-related-content.

  • The level change measures an immediate change after the onset of the pandemic.

  • The trend (slope) change measures a progressive increase or decrease in ASIRs in the pandemic period compared with the hypothetical continuations of the trends from the baseline period of March 2016 to February 2020.

  • § Includes Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and New Brunswick.

  • Includes Manitoba, Alberta and Saskatchewan.

  • ** Indicates that the trend change variable was not selected in the final model.